Pacira Pharmaceuticals Director Unloads $211,025 in Stock (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) Director Paul J. Hastings sold 2,500 shares of the stock on the open market in a transaction that occurred on Thursday, July 10th. The shares were sold at an average price of $84.41, for a total value of $211,025.00. Following the completion of the sale, the director now directly owns 853 shares in the company, valued at approximately $72,002. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
A number of research firms have recently commented on PCRX. Analysts at Canaccord Genuity initiated coverage on shares of Pacira Pharmaceuticals in a research note on Friday, June 27th. They set a “buy” rating and a $109.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at JMP Securities initiated coverage on shares of Pacira Pharmaceuticals in a research note on Tuesday, June 17th. They set a “market perform” rating on the stock. Finally, analysts at Goldman Sachs initiated coverage on shares of Pacira Pharmaceuticals in a research note on Monday, June 2nd. They set a “buy” rating and a $93.00 price target on the stock. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $81.80.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 1.10% on Friday, hitting $86.46. 397,236 shares of the company’s stock traded hands. Pacira Pharmaceuticals has a one year low of $30.75 and a one year high of $94.30. The stock’s 50-day moving average is $84.96 and its 200-day moving average is $72.54. The company’s market cap is $3.083 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, May 1st. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.13. The company had revenue of $36.70 million for the quarter, compared to the consensus estimate of $35.40 million. The company’s revenue for the quarter was up 216.4% on a year-over-year basis. On average, analysts predict that Pacira Pharmaceuticals will post $-0.53 earnings per share for the current fiscal year.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.